RBC Capital Reiterates Outperform on Intra-Cellular Therapies, Maintains $86 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Intra-Cellular Therapies (NASDAQ:ITCI), maintaining a price target of $86. This reaffirmation highlights the analyst's positive outlook on the company's stock.
February 23, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Intra-Cellular Therapies, with a maintained price target of $86, indicating a positive outlook on the stock.
The reiteration of an Outperform rating by a reputable analyst, along with the maintenance of a high price target, suggests a strong belief in the company's future performance. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100